Last reviewed · How we verify

CERC-301 — Competitive Intelligence Brief

CERC-301 (CERC-301) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: monoclonal antibody. Area: Autoimmune diseases, Oncology.

phase 2 monoclonal antibody CD28 Autoimmune diseases, Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CERC-301 (CERC-301) — Avalo Therapeutics, Inc.. CERC-301 is a monoclonal antibody targeting CD28 to modulate T-cell activation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CERC-301 TARGET CERC-301 Avalo Therapeutics, Inc. phase 2 monoclonal antibody CD28
Orencia abatacept Bristol-Myers Squibb marketed Selective T cell costimulation modulator CD80, CD86, CD28 2005-01-01
AML Y mg AML Y mg Celltrion phase 3 anti-CD28 monoclonal antibody CD28
PLA + MTX switched to ABA+ MTX, DB PLA + MTX switched to ABA+ MTX, DB Bristol-Myers Squibb phase 3 T-cell costimulation inhibitor CD80/CD86 (on antigen-presenting cells); CD28 (on T cells)
[89Zr]Zr-crefmirlimab berdoxam 89zr-zr-crefmirlimab-berdoxam Pfizer marketed Radiolabeled Monoclonal Antibody Fibroblast Activation Protein (FAP) Not specified
Venetoclax; Rituximab venetoclax-rituximab Pfizer marketed BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab) BCL-2 (venetoclax); CD20 (rituximab) N/A
Hympavzi MARSTACIMAB Pfizer Inc marketed Monoclonal Antibody Factor Xa 2025-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (monoclonal antibody class)

  1. Pfizer · 3 drugs in this class
  2. Avalo Therapeutics, Inc. · 1 drug in this class
  3. Bristol-Myers Squibb · 1 drug in this class
  4. Celltrion · 1 drug in this class
  5. Centocor, Inc. · 1 drug in this class
  6. Clinique des Céphalées de Montréal · 1 drug in this class
  7. Dermira, Inc. · 1 drug in this class
  8. European Organisation for Research and Treatment of Cancer - EORTC · 1 drug in this class
  9. Gliknik Inc. · 1 drug in this class
  10. Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CERC-301 — Competitive Intelligence Brief. https://druglandscape.com/ci/cerc-301. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: